BioNTech SE (BNTX)
| Market Cap | 27.35B |
| Revenue (ttm) | 3.70B |
| Net Income (ttm) | -670.66M |
| Shares Out | 250.93M |
| EPS (ttm) | -2.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,192,472 |
| Open | 109.24 |
| Previous Close | 106.07 |
| Day's Range | 107.91 - 111.26 |
| 52-Week Range | 81.20 - 126.77 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 140.31 (+28.73%) |
| Earnings Date | Nov 3, 2025 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Analyst Summary
According to 11 analysts, the average rating for BNTX stock is "Strong Buy." The 12-month stock price target is $140.31, which is an increase of 28.73% from the latest price.
News
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company's focus areas for 2026, including an overvie...
University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund
PHILADELPHIA--(BUSINESS WIRE)--The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative T...
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
MAINZ, Germany, December 18, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subse...
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart
BioNTech (BNTX) maintains a "Strong Buy" rating, driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3%...
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chem...
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expirati...
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
MAINZ, Germany, November 26, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the approval of matters relating to the exchange offer (the “Offer”) for all outstanding shares of CureVac N....
BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript
BioNTech SE ( BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies November 11, 2025 9:00 AM EST Company Participants Ugur Sahin - Co-Founder, C...
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up
Pfizer Inc said on Thursday said that it will sell 54.7% of its stake in German drugmaker BioNTech SE , over five years after both firms formed an alliance that yielded a vaccine to combat the deadly ...
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Pfizer (NYSE: PFE) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE (NASDAQ: BNTX).
BioNTech says collaboration with Pfizer remains unchanged
BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm.
BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold
BioNTech SE shared its Q3 earnings, business updates, and guidance for 2025 earlier today. Its share price is down 1% in trading so far. BNTX maintains a strong cash position, driven by ongoing Comirn...
BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript
BioNTech SE ( BNTX) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Douglas Maffei Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chie...
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
BioNTech SE (NASDAQ:BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings ...
BioNTech lifts 2025 revenue guidance on BMS partnership payment
Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge Merc...
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stages Demon...
BioNTech to Host Innovation Series R&D Day on November 11, 2025
MAINZ, Germany, October 28 , 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Sta...
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025....
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced it had commenced its public exchange offer (the “Offer”) for all outstanding shares of CureV...
Moderna Vs BioNTech: Who's Winning The Post-COVID Race
Moderna and BioNTech were the main 'saviors' of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%. Recognizing this, BioNTech and M...
BioNTech SE, InstaDeep Ltd - Special Call
BioNTech SE, InstaDeep Ltd - Special Call Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Karim Beguir Alexandre Laterre Bernardo Almeida Bora Guloglu Nicolas Lopez C...